To save the lives of mothers and their babies, mitigate complications, and limit the spread of disease, it is critical that recommendations are made on the prevention, treatment, and surveillance of women who are exposed to EVD, acquire EVD during pregnancy or breastfeeding, or survive EVD with ongo...ing pregnancies. These guidelines are the first to provide such recommendations.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Up-to-date Literature review current through: Jan 2015. | This topic last updated: Jan 29, 2015. 
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Supplement Article 
www.jaids.com J Acquir Immune Defic Syndr  Volume 78, Supplement 1, August 15, 2018
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                J Acquir Immune Defic Syndr  Volume 78, Supplement 1, August 15, 2018
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Research Article 
PLOS ONE | https://doi.org/10.1371/journal.pone.0190785 January 10, 2018 
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                In many countries neonatal tetanus is responsible for half of all neonatal deaths due to vaccine-preventable diseases and for almost 14% of al¡ infant deaths. It is estimated that in the 1970s more than 10,000 newborns died annually from neonatal tetanus in the Americas. Neonatal tetanus is prevent...ed by immunization and/or assuring clean delivery and post-delivery practices.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Recommendations for in-patient management of COVID-19 in adult patients 
Version 10, November 2020.
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                WHO and UNITAID
in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                 Bulletin of the World Health Organization, 2001, 79 (4)
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Development of one or more vaccines for Neisseria gonorrhoeae is an important objective for sexual and reproductive health worldwide, and for the fight against antimicrobial resistance.
WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vacci...nes in priority disease areas. PPCs are intended to encourage innovation and development of vaccines for use in settings most relevant to the global unmet public health need.
Gonococcal vaccine PPCs describe global public health goals for gonococcal vaccines and preferred parameters pertaining to vaccine indications and target populations, safety and efficacy considerations, and immunization strategies.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to international funding agencies, vaccine advisory groups, vaccine manufacturers, health professionals, researchers, the scientific media and the genera...l public.
Les notes de synthèse s’adressent aux responsables nationaux de la santé publique et aux administrateurs des programmes de vaccination, mais elles peuvent également présenter un intérêt pour les organismes internationaux de financement, les groupes consultatifs sur la vaccination, les fabricants de vaccins, les professionnels de la santé, les chercheurs, les médias scientifiques et le grand public.
                                                                    more